Ensysce Biosciences, Inc.
ENSC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -64% | 3.9% | 1.3% | – |
| Gross Profit | -$0 | -$0 | $0 | -$0 |
| % Margin | -499.2% | -40.2% | 100% | -191.7% |
| EBITDA | $0 | $0 | -$0 | $0 |
| % Margin | 3.7% | 0% | -147.1% | 0% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -756.3% | -126.4% | -147.4% | -273.4% |
| EPS Diluted | -1.29 | -0.79 | -1.39 | -2.9 |
| % Growth | -63.3% | 43.2% | 52.1% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |